198 related articles for article (PubMed ID: 9254514)
21. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
22. [Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes].
Khabarov SV; Gerasimova GK
Biokhimiia; 1996 Oct; 61(10):1866-73. PubMed ID: 9011234
[TBL] [Abstract][Full Text] [Related]
23. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
24. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
25. [Immunobiological activity of platinum coordination compounds in a complex with immunoglobulin fragments].
Plotnikov VM; Kazakov SA; Merkulov VG
Biull Eksp Biol Med; 1989 Sep; 108(9):313-5. PubMed ID: 2611387
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
[TBL] [Abstract][Full Text] [Related]
27. [Clinical pharmacology of anticancer agents. (Part 1) Introduction, alkylating agents and platinum compounds].
Fujita H
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2481-7. PubMed ID: 1952967
[TBL] [Abstract][Full Text] [Related]
28. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
Holmes J; Stanko J; Varchenko M; Ding H; Madden VJ; Bagnell CR; Wyrick SD; Chaney SG
Toxicol Sci; 1998 Dec; 46(2):342-51. PubMed ID: 10048138
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
30. [Present status of cisplatin (CDDP) analogues in Japan].
Majima H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1373-8. PubMed ID: 2658825
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
32. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of lactate-dehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro.
Hannemann J; Baumann K
Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):371-9. PubMed ID: 3175335
[TBL] [Abstract][Full Text] [Related]
34. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
35. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
[TBL] [Abstract][Full Text] [Related]
36. Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats.
Liu QF; Li X; Su Q; Luo GA; Wang YM; Liu WP
Arch Pharm Res; 2009 Nov; 32(11):1621-8. PubMed ID: 20091277
[TBL] [Abstract][Full Text] [Related]
37. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
38. Enhanced efficiency of the placental barrier to cisplatin through binding to glycocholic acid.
Pascual MJ; Macias RI; Garcia-Del-Pozo J; Serrano MA; Marin JJ
Anticancer Res; 2001; 21(4A):2703-7. PubMed ID: 11724343
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.
Wang X; Au-Yeung SC; Ho YP
J Inorg Biochem; 2007 Jun; 101(6):909-17. PubMed ID: 17428541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
